Supplementary Data:
Figure 1 Flow Diagram of Participants In the Hypertension In The Very Elderly Trial

Entered Placebo Run-in (n=4761)

Excluded (n=916)

Reasons:
In Run-in phase when trial stopped 59
Eligible but not randomized as trial stopped 12
Died 30
Withdraw consent 280
Protocol criteria not met 461
Centre closed 65
Centre quota reached 9

Enrollment

Randomised (n=3845)

Allocated to active intervention (n=1933)

Received allocated intervention (n=1929)
Did not receive allocated intervention (n=4)

Allocated to Placebo intervention (n=1912)

Received allocated intervention (n=1906)
Did not receive allocated intervention (n=6)

Allocation

Lost to follow-up (n=6)
Died (n=196)
Discontinued intervention (n=645)
Alive at end of trial (n=1086)

Lost to follow-up (n=11)
Died (n=235)
Discontinued intervention (n=650)
Alive at end of trial (n=1016)

Follow-Up

ITT Analysis (n=1933)
PP Analysis (n=1922)
Excluded from PP analysis (n=11)
Randomized in error 6
Did not receive correct treatment 4
Randomized to wrong strata 1

ITT Analysis (n=1912)
PP Analysis (n=1900)
Excluded from PP analysis (n=12)
Randomized in error: 4
Did not receive correct treatment: 6
Randomized to wrong strata: 1
Code broken before randomisation: 1

Analysis
Supplementary Data:
Figure 2  A graph showing cumulative hazard of fracture over time for the two treatment groups (active and placebo)